EMA, Biopharma Industry Clash on Clinical Trial Data

The European Medicines Agency (EMA) and the pharmaceutical industry look to be set on a collision course regarding the vexed issue of access to clinical trial data, following the joint publication of a set of principles on the topic by the Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

To continue reading subscribe now to BioWorld Asia (formerly International)